| Syed Adil Kamal, MD | |
|
59 North Ct, Roslyn Heights, NY 11577-2110 | |
| (631) 332-0686 | |
| Not Available |
| Full Name | Syed Adil Kamal |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 22 Years |
| Location | 59 North Ct, Roslyn Heights, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013232396 | NPI | - | NPPES |
| 03225252 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | 256574 (New York) | Secondary |
| 207R00000X | Internal Medicine | 256574 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Medical Center | Rockville centre, NY | Hospital |
| The Grand Pavilion For Rhb & Nrsg At Rockville Ctr | Rockville centre, NY | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Suffolk Medical Pc | 0244396349 | 138 |
News Archive
Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.
In a surprising discovery with implications for treating muscular dystrophy, researchers at the University of Utah School of Medicine and other institutions have identified a major source of origin for two groups of adult cells that regulate muscle repair.
Visits to the UK's woodlands boosts mental health and is estimated to save £185 million in treatment costs annually, a landmark report published by Forest Research finds today (4 December).
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.
› Verified 6 days ago
| Entity Name | Southwest Suffolk Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104096049 PECOS PAC ID: 0244396349 Enrollment ID: O20090225000297 |
News Archive
Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.
In a surprising discovery with implications for treating muscular dystrophy, researchers at the University of Utah School of Medicine and other institutions have identified a major source of origin for two groups of adult cells that regulate muscle repair.
Visits to the UK's woodlands boosts mental health and is estimated to save £185 million in treatment costs annually, a landmark report published by Forest Research finds today (4 December).
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.
› Verified 6 days ago
| Entity Name | Lawrence Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023257441 PECOS PAC ID: 1759439631 Enrollment ID: O20090504000017 |
News Archive
Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.
In a surprising discovery with implications for treating muscular dystrophy, researchers at the University of Utah School of Medicine and other institutions have identified a major source of origin for two groups of adult cells that regulate muscle repair.
Visits to the UK's woodlands boosts mental health and is estimated to save £185 million in treatment costs annually, a landmark report published by Forest Research finds today (4 December).
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Syed Adil Kamal, MD 59 North Ct, Roslyn Heights, NY 11577-2110 Ph: (631) 332-0686 | Syed Adil Kamal, MD 59 North Ct, Roslyn Heights, NY 11577-2110 Ph: (631) 332-0686 |
News Archive
Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.
In a surprising discovery with implications for treating muscular dystrophy, researchers at the University of Utah School of Medicine and other institutions have identified a major source of origin for two groups of adult cells that regulate muscle repair.
Visits to the UK's woodlands boosts mental health and is estimated to save £185 million in treatment costs annually, a landmark report published by Forest Research finds today (4 December).
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.
› Verified 6 days ago
Dr. Anitha Sara Mathew-shaji, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 Glen Cove Rd Ste 301, Roslyn Heights, NY 11577 Phone: 516-621-1502 Fax: 516-621-1162 | |
Frank R Vezza, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 4 Mineola Ave, Roslyn Heights, NY 11577 Phone: 516-621-9463 Fax: 516-621-9469 | |
Dr. Helen Mary Marks, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6 Helen Dr, Roslyn Heights, NY 11577 Phone: 516-626-2559 Fax: 516-626-9552 | |
Tanzina Nashid, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 232 Round Hill Rd, Roslyn Heights, NY 11577 Phone: 678-557-3274 Fax: 678-557-3274 | |
Dr. Daniel Gilead Kassan, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 70 Glen Cove Rd, Suite #306, Roslyn Heights, NY 11577 Phone: 516-621-7720 Fax: 516-625-4521 | |
Dr. Ethan David Loeb, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 19 Sycamore Ln, Roslyn Heights, NY 11577 Phone: 504-606-7612 |